Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

2.1K

[Research advances in pediatric nonalcoholic fatty liver disease]

Dong-Ling Dai1

  • 1Department of Gastroenterology, Shenzhen Children's Hospital, Shenzhen, Guangdong 518036, China. daidong3529@sina.com.

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|January 25, 2015
PubMed

Insights

Pediatric nonalcoholic fatty liver disease (NAFLD) is rising due to childhood obesity. New non-invasive scores aid diagnosis, with lifestyle changes being the primary treatment for this common liver condition.

Area of Science:

  • Hepatology
  • Pediatrics
  • Metabolic Disorders

Context:

  • Rising prevalence of childhood obesity and overweight contributing to increased nonalcoholic fatty liver disease (NAFLD).
  • NAFLD is now the most common chronic liver disease in children, driving expanded research.
  • Genetic, dietary, and environmental factors are implicated in pediatric NAFLD development.

Purpose:

  • To review current knowledge and concepts regarding pediatric NAFLD.
  • To discuss advancements in the diagnosis of pediatric NAFLD.
  • To explore emerging therapies and scoring methods for pediatric NAFLD.

Summary:

  • The "two-hit" and "multiple-hit" hypotheses are widely accepted for NAFLD pathogenesis.
  • Despite research, a definitive non-invasive diagnostic marker for pediatric NAFLD is lacking.
  • New non-invasive prediction scores have been developed, and lifestyle intervention is the recommended therapy.

Impact:

  • Highlights the need for improved non-invasive diagnostic tools for pediatric NAFLD.
  • Emphasizes the importance of lifestyle interventions in managing pediatric NAFLD.
  • Provides an overview of current research and future directions in pediatric NAFLD.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

2.0K

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.2K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
371
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
886
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
513
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
3